Fulzos 250mg Injection (Fulvestrant)

Fulzos 250 mg Injection is an anti-hormonal drug that contains fulvestrant as an active ingredient. The medicine used in the treatment of hormone receptor-positive breast cancer in postmenopausal women by attaching to estrogen receptors and decreasing their numbers. Each 5 ml of injection contains 250 mg of fulvestrant injection dose.

However, the typical dosage for therapy is 500 mg and is administered in two 250 mg doses intramuscularly deep in both buttocks. In line with the patient's clinical status and prior treatment with hormonal drugs, a fulvestrant 250mg injection may be prescribed in combination with targeted drugs like CDK4/6 inhibitors. Therefore, patients are advised to use the medication under healthcare professionals.

Fulvestrant 250mg Injection is used in:

• ER-positive, HER2-negative advanced breast cancer
• ER-positive, HER2-negative metastatic breast cancer

The medicine is usually prescribed for postmenopausal women. Fulzos 250 mg Injection is usually used when the patient shows signs of progression despite previous endocrine therapy. It is also sometimes used in combination with target drugs, such as CDK4/6 inhibitors, depending on the patient's condition and treatment plan.

The mode of action for Fulvestrant Injection involves binding to the hormone receptors found on the breast cancer cells in order to inhibit their activity. The medicine also helps in breaking down and reducing the number of these hormone receptors, which decreases hormone-related signaling and can slow the growth of hormone-sensitive breast cancer cells.

CONFIRM: This research indicated that the 500mg dosage of fulvestrant injection was superior to the previously used 250mg dosage. Therefore, the 500mg dosage should be considered the standard dosage.

FALCON: Two Fulzos 250 mg Injection achieved superior disease control compared to anastrozole among the patients with advanced estrogen receptor-positive breast cancer that had never been treated with endocrine therapy before.

PALOMA-3: This study proved the advantage of administering two fulvestrant 250mg injection in combination with palbociclib to those individuals who no longer respond to their hormone therapy.

The side effects might differ from one individual to another. Although some side effects are minor and short-lived, there are some symptoms that need immediate attention from a doctor:

Common / expected side effects

• Injection-site pain
• Nausea
• Fatigue
• Hot flushes
• Headache
• Bone/joint/muscle pain
• Elevated liver enzymes

Serious side effects

• Bleeding/haematoma after IM injection
• Severe hepatic reactions
• Hypersensitivity
• Sciatic nerve injury/neuropathic symptoms (rare)
  

​Important: This is just a general guide for treatment. The physician will determine the correct dose, schedule, combination of drugs, dosage adjustment due to organ dysfunction, and the handling of side effects, depending on the individual patient.

If the Fulzos 250 mg injection appointment is missed, please contact the oncology clinic for guidance on how to proceed. Never take additional injections to cover up the missed one. It will be decided by the medical professionals when to give your next dose, particularly when missing an injection during your first dosing cycle.

In case of treatment, periodic monitoring will help the physician assess the efficiency, safety, and possible side effects of Fulvestrant 250mg injection:

• Evaluation of symptoms, physical examination, or imaging to assess the efficiency of the treatment.
• Monitoring of liver function if necessary.
• Checking the injection site for pain and bleeding.
• Evaluating ovarian suppression if applicable.
  

• Nathan, M. R., & Schmid, P. (2017). A review of fulvestrant in breast cancer. Oncology and therapy, 5(1), 17-29. https://link.springer.com/article/10.1007/s40487-017-0046-2​
• Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., ... & Cristofanilli, M. (2018). Overall survival with palbociclib and fulvestrant in advanced breast cancer. New England journal of medicine, 379(20), 1926-1936. https://pubmed.ncbi.nlm.nih.gov/30345905/​
• Hart, C. D., Migliaccio, I., Malorni, L., Guarducci, C., Biganzoli, L., & Di Leo, A. (2015). Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nature reviews Clinical oncology, 12(9), 541-552.  https://www.ovid.com/journals/ntrco/abstract/10.1038/nrclinonc.2015.99~challenges-in-the-management-of-advanced-er-positive?redirectionsource=fulltextview​
• Howell, A., & Sapunar, F. (2011). Fulvestrant revisited: efficacy and safety of the 500-mg dose. Clinical breast cancer, 11(4), 204-210.  https://www.sciencedirect.com/science/article/abs/pii/S1526820911000206​
• McKeage, K., Curran, M. P., & Plosker, G. L. (2004). Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs, 64(6), 633-648.  https://pubmed.ncbi.nlm.nih.gov/21319872/​